This fast track antibody is not yet fully characterized. It is subject to these terms and conditions


  • Product nameAnti-PML+RARA Fusion antibody
  • Description
    Rabbit polyclonal to PML+RARA Fusion

    This product is a fast track antibody. It has been affinity purified and shows high titre values against the immunizing peptide by ELISA. Read the terms of use »

  • Species reactivity

    Predicted to work with: Human
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 500 - 600 of Human PML+RARa Fusion. This peptide comprises the region across the PML-RAR alpha junction in the L-type fusion protein.

    (Peptide available as ab46898.)



Fast track antibodies constitute a diverse group of products that have been released to accelerate your research, but are not yet fully characterized. They have all been affinity purified and show high titre values against the immunizing peptide (by ELISA). Fast track terms of use

Application Abreviews Notes
WB 1/5000.


  • RelevancePML protein is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This phosphoprotein localizes to nuclear bodies where it functions as a transcription factor and tumor suppressor. Its expression is cell-cycle related and it regulates the p53 response to oncogenic signals. Retinoic acid, a metabolite of vitamin A, is necessary for normal organogenesis but acts as a teratogen at high levels during embryonic and fetal development. Retinoic acid functions through its interaction with the nuclear protein, retinoic acid receptor (RAR). RAR belongs to the steroid and thyroid hormone superfamily of nuclear receptor proteins which exert their effects by binding to specific DNA response elements, thus regulating gene expression in target cells. RAR exists as three major subtypes: alpha, beta and gamma.
  • Cellular localizationNuclear and Cytoplasmic
  • Database links
  • Alternative names
    • MYL antibody
    • NR1B1 antibody
    • Nuclear receptor subfamily 1 group B member 1 antibody
    • Nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form antibody
    • PP8675 antibody
    • Promyelocytic leukemia antibody
    • Promyelocytic leukemia protein antibody
    • Promyelocytic leukemia, inducer of antibody
    • RAR antibody
    • RAR-alpha antibody
    • RARA alpha antibody
    • RARAalpha1 antibody
    • Retinoic acid receptor alpha polypeptide antibody
    • Retinoic acid receptor, alpha antibody
    • RING finger protein 71 antibody
    • RNF71 antibody
    • TRIM19 antibody
    • Tripartite motif protein TRIM19 antibody
    • Tripartite motif-containing protein 19 antibody
    see all

Anti-PML+RARA Fusion antibody images

This Fast-Track antibody is not yet fully characterised. These images represent inconclusive preliminary data.

  • Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 100 kDa
    Additional bands at : 130 kDa (possible Fusion protein),40 kDa (possible cross reactivity),53 kDa (possible cross reactivity),85 kDa (possible cross reactivity).

    Image courtesy of Christian Marx (University of Jena, Germany)

    Anti-PML+ RARα Fusion antibody (ab43152) reactivity with reduced NB4 (A and B) and K562 (B) cell lysate. After SDS-PAGE (where 100μg lysate was loaded in A and 20μg lysate in B), membranes were blocked in 5% Milk in PBS + 0.1% Tween for 1h at 25°C before incubation with ab43152 (1:5,000 dilution in 1% Milk PBS + 0.1% Tween) for 16h at 4ºC. Blots was then incubated with an anti-Rabbit HRP-conjugated secondary antibody before developing with ECL.

    See Abreview

References for Anti-PML+RARA Fusion antibody (ab43152)

This product has been referenced in:
  • Li X  et al. Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line. J Int Med Res 44:882-92 (2016). Read more (PubMed: 27189198) »
  • Ying M  et al. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARa/STAT1 axis. Mol Cancer Ther 12:195-206 (2013). WB ; Human . Read more (PubMed: 23243061) »

See all 3 Publications for this product

Product Wall

Application Western blot
Loading amount 100 µg
Gel Running Conditions Reduced Denaturing (8 %)
Sample Human Cell lysate - whole cell (NB4 and K562 human cell lines)
Specification NB4 and K562 human cell lines
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Mr. Christian Marx

Verified customer

Submitted Jul 31 2013

Thank you for enquiry and your interest.
This product is Fast track and as these antibodies have not been fully characterized at Abcam, we cannot guarantee that the antibody will work in any application other than ELISA against the immunizing pept...

Read More

Merci de nous avoir contactés. Nous sommes désolés d'apprendre que le produit que vous avez reçu ne fonctionne pas comme attendu. Nous allons vous remplacer volontiers ce tube fautif avec un nouveau tube. Veuillez me confirmer pour ceci votre numéro et...

Read More

Thank you for taking the time to complete our questionnaire and contact us. I am sorry to hear you have had difficulty obtaining satisfactory results from this antibody. The details you have kindly provided will enable us to investigate this case f...

Read More